| DRUG | COMPANY | OTHER INDICATIONS | U.S. DEVELOPM. STATUS |
|---|---|---|---|
| ALCAR acetyl-carnitine | Sigma-Tau (Gaithersburg,MD) | Phase III HCL | |
| AVIVA linopirdine | Du Pont Merck (Wilmington, DE) | cognition enhancement | Phase III |
| BC-PS phosphatidylserine | Fidia Pharmaceutical (Washington, DC) | Phase II | |
|
besipirdine HCL (HP 749) | Hoechst-Roussel (Somerville, NJ) | Phase II | |
| cholinesterase inhibitor | Marion Merrell Dow (Kansas City, MO) | Phase II | |
| Cl-979 | Warner-Lambert (Morris Plains, NJ) | Phase II | |
| Cognex Tacrine | Warner-Lambert (Morris Plains, NJ) | application submitted [FDA approved]* | |
| ENS-163 | Sandoz (East Hanover, NJ) | Phase I | |
| ENS-713 | Sandoz (East Hanover, NJ) | Phase II | |
| inverse GABA agonist | Marion Merrell Dow (Kansas City, MO) | also depression | Phase II |
| lazabemide | Hoffmann- La Roche (Nutley, NJ) | also Parkinson's | in clinical trials |
| levacecarnine | Hoffman-La Roche (Nutley, NJ) | Phase III | |
| LY 246078 | Eli Lilly (Indianapolis, IN) | Phase II | |
| MAO-B inhibitor | Marion Merrell Dow (Kansas City, MO) | also Parkinson's | Phase II |
|
Mentane velnacrine maleate | Hoechst-Roussel (Somerville, NJ) | [no longer produced]* | Phase III application submitted |
| Nimotop nimodipine | Miles Inc. Pharmaceutical Division (West Haven, CT) | Phase III | |
| ondanserion | Glaxo Rsch. (Triangle Park, NC) | Phase III | |
| sabeluzole | Janssen Pharmaceutica (Titusville, NJ) | Phase II | |
| Synapton physostigmine salicylate | Forest Laboratories (New York, NY) | Phase III | |
| Source: 1993 Survey, "New Medicines in Development for Older Americans," Presentato da the Pharmaceutical Manufacturers Association. | |||
*EDITOR'S NOTE: At this posting, August 9, 1994, Cognex
Tacrine has received FDA approval, and Mentane is no longer produced.
If you would like to receive a copy of the 1993 Survey, the Pharmaceutical Manufacturer's Association has a FAX-on-Demand service available.
Dial from your fax machine 001-202 895-6060. Follow voice instructions. The 1993 Survey on Alzheimer's and Other Debilitating Diseases is 16 pages long -- document number 3008.